FAMCICLOVIR

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H19N5O4
Molecular Weight	321.3318
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O

InChI

InChIKey=GGXKWVWZWMLJEH-UHFFFAOYSA-N

InChI=1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18)

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020629s016lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3040998 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020363s037lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/2754699

Penciclovir (DENAVIR®) is a synthetic acyclic guanine derivative with antiviral activity, mainly used to treat infections from herpes simplex virus (HSV) types 1 and 2. In cells infected with HSV-1 or HSV-2, the viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted by cellular kinases to the active form penciclovir triphosphate. Biochemical studies demonstrate that penciclovir triphosphate inhibits HSV polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited. Famciclovir (FAMVIR®) is a prodrug form of penciclovir with improved oral bioavailability.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human herpesvirus 1 DNA polymerase 19 Target ID: CHEMBL1872 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020629s016lbl.pdf	Inhibitor 8297		16.0 µM [Ki]
DNA polymerase catalytic subunit 14 Target ID: P89453 Gene ID: 1487316.0 Gene Symbol: NA Target Organism: Human herpesvirus 2 (strain HG52) (HHV-2) (Human herpes simplex virus\|\|\|2) Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020629s016lbl.pdf	Inhibitor 8297		9.5 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Recurrent herpes labialis 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020629s016lbl.pdf	Primary		Approved 8429	DENAVIR Approved Use DENAVIR® is a nucleoside analog HSV DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in adults and children 12 years of age and older. Launch Date 1996

C_max

Value	Dose	Analyte	Population
0 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020629s016lbl.pdf	1.8 mg single, topical dose: 1.8 mg route of administration: Topical experiment type: SINGLE co-administered:	PENCICLOVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020629s016lbl.pdf	1.8 mg 1 times / day steady-state, topical dose: 1.8 mg route of administration: Topical experiment type: STEADY-STATE co-administered:	PENCICLOVIR plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
6.6 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	PENCICLOVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.6 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	PENCICLOVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.3 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	PENCICLOVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	PENCICLOVIR unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.9 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered:	PENCICLOVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
17.9 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	PENCICLOVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.48 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	PENCICLOVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
8.95 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	PENCICLOVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
12.1 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	PENCICLOVIR unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.24 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered:	PENCICLOVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		PENCICLOVIR unknown	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1 % 12 times / day multiple, topical Recommended Dose: 1 %, 12 times / day Route: topical Route: multiple Dose: 1 %, 12 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020629Orig1s000rev.pdf Page: Study 024	unhealthy, 39 n = 782 Health Status: unhealthy Condition: Recurrent Herpes Simplex Labialis Age Group: 39 Sex: M+F Population Size: 782 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020629Orig1s000rev.pdf Page: Study 024	Disc. AE: Dissociative disorder... AEs leading to discontinuation/dose reduction: Dissociative disorder Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020629Orig1s000rev.pdf Page: Study 024
750 mg 3 times / day multiple, oral MTD Dose: 750 mg, 3 times / day Route: oral Route: multiple Dose: 750 mg, 3 times / day Sources: https://www.medsafe.govt.nz/Profs/Datasheet/a/APOHEALTHFamciclovirOncetab.pdf https://www.ema.europa.eu/en/documents/referral/famvir-article-30-referral-assessment-report_en.pdf	unhealthy Health Status: unhealthy Condition: Herpes zoster Sources: https://www.medsafe.govt.nz/Profs/Datasheet/a/APOHEALTHFamciclovirOncetab.pdf https://www.ema.europa.eu/en/documents/referral/famvir-article-30-referral-assessment-report_en.pdf	Sources: https://www.medsafe.govt.nz/Profs/Datasheet/a/APOHEALTHFamciclovirOncetab.pdf https://www.ema.europa.eu/en/documents/referral/famvir-article-30-referral-assessment-report_en.pdf
1500 mg single, oral Recommended Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020363s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Herpes labialis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020363s037lbl.pdf Page: p.1	Other AEs: Acute renal failure... Other AEs: Acute renal failure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020363s037lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Dissociative disorder	Disc. AE	1 % 12 times / day multiple, topical Recommended Dose: 1 %, 12 times / day Route: topical Route: multiple Dose: 1 %, 12 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020629Orig1s000rev.pdf Page: Study 024	unhealthy, 39 n = 782 Health Status: unhealthy Condition: Recurrent Herpes Simplex Labialis Age Group: 39 Sex: M+F Population Size: 782 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020629Orig1s000rev.pdf Page: Study 024
Acute renal failure		1500 mg single, oral Recommended Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020363s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Herpes labialis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020363s037lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MATE2 263 OCT2 647 MATE1 306	aldehyde oxidase 16 esterase 72 CYP 270 OAT2 115 OATP1B1 406 OATP1B3 350 OATP2B1 104 NTCP 17 OCT1 327	OCT2 6 MATE2 5 MATE1 6

Drug as perpetrator

Target	Modality	Activity
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020363s050lbl.pdf#page=6 Page: 6.0	no
MATE1 308	inducer 1573 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792735/	no
MATE1 308	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792735/	no
MATE2 263	inducer 1573 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792735/	no
OCT2 648	inducer 1573 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792735/	no
OCT2 648	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792735/	no
MATE2 263	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792735/	yes

Drug as victim

Target	Modality	Activity
CYP 270	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-363S-019_review.pdf#page=7 Page: 7.0	no
NTCP 17	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28945155/	no
OATP1B1 406	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28945155/	no
OATP1B3 350	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28945155/	no
OATP2B1 104	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28945155/	no
OCT1 327	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28945155/	no
CYP 270	substrate 3367 Sources: https://pdf.hres.ca/dpd_pm/00029892.PDF#page=13 Page: 13.0	yes
OAT2 115	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/28945155/	yes
aldehyde oxidase 16	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9224775/	yes
esterase 72	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/27298339/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4974	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4974
ChEBI	CHEBI:7956	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7956
ChemicalBook	CB0464901	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0464901
ChemicalBook	CB7731886	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7731886
MolPort	MolPort-003-666-602	https://www.molport.com/shop/molecule-link/MolPort-003-666-602
MolPort	MolPort-003-849-798	https://www.molport.com/shop/molecule-link/MolPort-003-849-798
MolPort	MolPort-006-167-513	https://www.molport.com/shop/molecule-link/MolPort-006-167-513
Selleck Chemicals	Famciclovir(Famvir)	http://www.selleckchem.com/products/Famciclovir(Famvir).html
Selleck Chemicals	penciclovir	http://www.selleckchem.com/products/penciclovir.html
ZINC	ZINC000000001899	http://zinc15.docking.org/substances/ZINC000000001899
ZINC	ZINC000001530635	http://zinc15.docking.org/substances/ZINC000001530635
eMolecules	32456333	https://www.emolecules.com/cgi-bin/more?vid=32456333
eMolecules	901871	https://www.emolecules.com/cgi-bin/more?vid=901871
eMolecules	902282	https://www.emolecules.com/cgi-bin/more?vid=902282

PubMed

Title	Date	PubMed
Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents.	2001 Apr-Jul	11563039
Antiviral drugs: current state of the art.	2001 Aug	11418355
Recent developments in herpesvirus therapy.	2001 Mar	11867011
Herpes simplex virus: clinical presentation and treatment.	2001 May	11443814
Separation methods for acyclovir and related antiviral compounds.	2001 Nov 25	11817033
Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8.	2001 Nov-Dec	11747000
A simplified one-pot synthesis of 9-[(3-[18F]fluoro-1-hydroxy-2-propoxy)methyl]guanine([18F]FHPG) and 9-(4-[18F]fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG) for gene therapy.	2001 Oct	11578910
Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection.	2001 Sep	11559210
Viral diseases of the skin: diagnosis and antiviral treatment.	2002	11817982
[Local treatments using antiviral and non-antiviral drugs for herpes facialis and genitalis (excluding pregnant females and neonates at risk)].	2002 Apr	12122334
[Genital herpes: epidemiology, transmission, clinic, asymptomatic viral excretion, impact on other sexually transmitted diseases, prevention, and treatment].	2002 Apr	12122319
Temporal pattern of herpes simplex virus type 1 infection and cell death in the mouse brain stem: influence of guanosine nucleoside analogues.	2002 Apr	11879697
Studies on the thermal decomposition process and kinetics of purine drugs.	2002 Aug	12567782
Comparative analysis of DNA breakage, chromosomal aberrations and apoptosis induced by the anti-herpes purine nucleoside analogues aciclovir, ganciclovir and penciclovir.	2002 Aug 29	12175901
New treatments for genital herpes.	2002 Feb	11964906
Drugs for non-HIV viral infections.	2002 Feb 4	11828264
Herpes simplex virus infection.	2002 Jan	12118847
Comparison of methods for identifying resistant herpes simplex virus and measuring antiviral susceptibility.	2002 Jan	11595598
Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial.	2002 Jun	12060504
Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials.	2002 Mar	11934185
The A167Y mutation converts the herpes simplex virus type 1 thymidine kinase into a guanosine analogue kinase.	2002 May 21	12009916
Assessing the contribution of the herpes simplex virus DNA polymerase to spontaneous mutations.	2002 May 7	12019036
Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs.	2002 Oct	12271305
CL1-SR39: A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography.	2002 Sep	12187266
[4'-Thio-5-ethyl-2'-deoxyuridine 5'-phosphonates: synthesis and antiviral activity].	2002 Sep-Oct	12408030
Current and potential therapies for the treatment of herpes-virus infections.	2003	12790345
MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts.	2003 Apr 1	12640659
Molecular imaging of protein-protein interactions: controlled expression of p53 and large T-antigen fusion proteins in vivo.	2003 Apr 15	12702563
Susceptibility of herpes simplex virus isolates to nucleoside analogues and the proportion of nucleoside-resistant variants after repeated topical application of penciclovir to recurrent herpes labialis.	2003 Apr 15	12696003
Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster.	2003 Aug	15482124
Novel agents and strategies to treat herpes simplex virus infections.	2003 Feb	12556212
In vitro activity of potential anti-poxvirus agents.	2003 Jan	12615301
Herpes simplex virus resistance to antiviral drugs.	2003 Jan	12589832
Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.	2003 Jun	12760870
The role of stratum corneum and dermal microvascular perfusion in penetration and tissue levels of water-soluble drugs investigated by microdialysis.	2003 Mar	12653734
Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing.	2003 May	12861349
Optimization of cellular nucleotide extraction and sample preparation for nucleotide pool analyses using capillary electrophoresis.	2003 May 5	12668076
Comparison of [18F]FHBG and [14C]FIAU for imaging of HSV1-tk reporter gene expression: adenoviral infection vs stable transfection.	2003 Nov	14579096
Recurrent herpes simplex labialis: selected therapeutic options.	2003 Sep	12954137
In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1.	2004 Apr	15077679
Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial.	2004 Apr	15018852
Synthesis and biological evaluation of novel tert-azido or tert-amino substituted penciclovir analogs.	2004 Apr 21	15064793
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir.	2004 Aug	15271515
Can clinical trials requiring frequent participant contact be conducted over the Internet? Results from an online randomized controlled trial evaluating a topical ointment for herpes labialis.	2004 Feb 17	15111272
Therapeutic options for herpes labialis, II: Topical agents.	2004 Jul	15293698
Antiviral drugs in current clinical use.	2004 Jun	15125867
Penciclovir cream--improved topical treatment for herpes simplex infections.	2004 Sep-Oct	15452407
Platinum(II) complexes with antitumoral/antiviral aromatic heterocycles: effect of glutathione upon in vitro cell growth inhibition.	2005 May 5	15857142
Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial.	2005 Oct 15	16163627
In vitro activity of cycloSal-nucleoside monophosphates and polyhydroxycarboxylates against orthopoxviruses.	2005 Sep	16076502

Patents

Sample Use Guides

In Vivo Use Guide

Penciclovir (DENAVIR®) should be applied every 2 hours during waking hours for a period of 4 days. Treatment should be started as early as possible (i.e., during the prodrome or when lesions appear).

Route of Administration: Topical

In Vitro Use Guide

In cell culture studies, penciclovir has antiviral activity against the following herpes viruses: HSV-1 and HSV-2. The antiviral activity of penciclovir against wild type strains grown on human foreskin fibroblasts was assessed with a plaque reduction assay and staining with crystal violet 3 days postinfection for HSV. The median EC50 values of penciclovir against laboratory and clinical isolates of HSV-1 and HSV-2 were 2 uM (range 1.2 to 2.4 uM, n=7) and 2.6 uM (range 1.6 to 11 uM, n=6), respectively.

Name

Type

Language

FAMCICLOVIR

Official Name

English

FAMCICLOVIR [JAN]

Common Name

English

2-[2-(2-Amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate (ester)

Common Name

English

FAMCICLOVIR [MART.]

Common Name

English

Famciclovir [WHO-DD]

Common Name

English

1,3-PROPANEDIOL, 2-(2-(2-AMINO-9H-PURIN-9-YL)ETHYL)-, DIACETATE (ESTER)

Common Name

English

BRL-42810

Code

English

NSC-758921

Code

English

FAMCICLOVIR [USP MONOGRAPH]

Common Name

English

famciclovir [INN]

Common Name

English

FAMCICLOVIR [USP-RS]

Common Name

English

FAMCICLOVIR [MI]

Common Name

English

FAMCICLOVIR [ORANGE BOOK]

Common Name

English

FAMCICLOVIR [USAN]

Common Name

English

FAMCICLOVIR [VANDF]

Common Name

English

FAMVIR

Brand Name

English

Classification Tree Code System Code

WHO-ATC

J05AB09

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

WHO-ATC

S01AD07

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

NDF-RT

N0000020060

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

NDF-RT

N0000180187

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

LIVERTOX

NBK547978

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

NDF-RT

N0000175459

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

WHO-VATC

QS01AD07

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

WHO-VATC

QJ05AB09

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

NDF-RT

N0000175459

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

NCI_THESAURUS

C29575

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

NCI_THESAURUS

C281

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

NDF-RT

N0000175459

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

Code System Code Type Description

MESH

C060590

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

MERCK INDEX

m5240

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

Merck Index

NCI_THESAURUS

C29044

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

EVMPD

SUB07501MIG

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

USAN

EE-84

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

HSDB

8121

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

CHEBI

4974

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

DAILYMED

QIC03ANI02

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

INN

6438

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

DRUG CENTRAL

1128

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

CAS

104227-87-4

Created by admin on Sat Dec 16 05:09:16 GMT 2023 , Edited by admin on Sat Dec 16 05:09:16 GMT 2023

PRIMARY

NSC

758921

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

SMS_ID

100000092280

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

RXCUI

68099

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

RxNorm

WIKIPEDIA

FAMCICLOVIR

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

LACTMED

Famciclovir

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

DRUG BANK

DB00426

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

FDA UNII

QIC03ANI02

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

ChEMBL

CHEMBL880

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

EPA CompTox

DTXSID0023038

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

RS_ITEM_NUM

1269152

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

PUBCHEM

3324

Created by admin on Sat Dec 16 05:09:17 GMT 2023 , Edited by admin on Sat Dec 16 05:09:17 GMT 2023

PRIMARY

ACTIVE MOIETY


					359HUE8FJC

PENCICLOVIR

METABOLITE INACTIVE (PARENT)


					N8C09G1O3O

6-DEOXYPENCICLOVIR

SUBSTANCE RECORD


					QIC03ANI02

FAMCICLOVIR

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

Drug as perpetrator